We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.19%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$811M
AUM Growth
+$71.2M
Cap. Flow
+$48M
Cap. Flow %
5.92%
Top 10 Hldgs %
28.89%
Holding
102
New
7
Increased
37
Reduced
34
Closed
10

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$18.2M
2
BDX icon
Becton Dickinson
BDX
+$16.8M
3
BMY icon
Bristol-Myers Squibb
BMY
+$14.2M
4
CELG
Celgene Corp
CELG
+$13M
5
CI icon
Cigna
CI
+$12.6M

Top Sells

Rank Stock Value
1
ADMS
Adamas Pharmaceuticals
ADMS
+$15.2M
2
NKTR icon
Nektar Therapeutics
NKTR
+$12.5M
3
ESPR
Esperion Therapeutics
ESPR
+$10.4M
4
COR icon
Cencora
COR
+$6.72M
5
UHS icon
Universal Health Services
UHS
+$5.94M

Sector Composition

Rank Sector Weight
1 Healthcare 94.68%
2 Technology 0.23%
3 Energy 0.22%
4 Financials 0.18%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$28.5M 3.51%
2,007,212
+52,300
+3% +$773K
CELG
2
DELISTED
Celgene Corp
CELG
$26.4M 3.26%
296,412
+135,000
+84% +$13M
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$24.7M 3.05%
221,863
+70,000
+46% +$8.37M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$121B
$24.4M 3.01%
150,000
-2,204
-1% -$360K
JAZZ icon
5
Jazz Pharmaceuticals
JAZZ
$15.9B
$22.4M 2.76%
148,436
+15,000
+11% +$2.2M
ABMD
6
DELISTED
Abiomed Inc
ABMD
$22.3M 2.74%
76,490
-10,000
-12% -$2.53M
BMY icon
7
Bristol-Myers Squibb
BMY
$133B
$22.1M 2.73%
350,000
+220,198
+170% +$14.2M
NKTR icon
8
Nektar Therapeutics
NKTR
$2.39B
$22M 2.72%
13,831
-9,736
-41% -$12.5M
EXEL icon
9
Exelixis
EXEL
$13.3B
$21.8M 2.69%
986,214
+230,000
+30% +$6.36M
ABBV icon
10
AbbVie
ABBV
$443B
$19.6M 2.41%
206,700
+50,000
+32% +$5.49M
CI icon
11
Cigna
CI
$73.7B
$18.5M 2.28%
110,400
+65,000
+143% +$12.6M
HUM icon
12
Humana
HUM
$43.7B
$18.3M 2.25%
68,000
+10,000
+17% +$2.71M
GILD icon
13
Gilead Sciences
GILD
$162B
$17.9M 2.2%
237,027
-48,724
-17% -$3.87M
ESPR
14
DELISTED
Esperion Therapeutics
ESPR
$17.7M 2.18%
244,540
-142,086
-37% -$10.4M
UNH icon
15
UnitedHealth
UNH
$376B
$17.3M 2.14%
81,000
+5,500
+7% +$1.26M
LLY icon
16
Eli Lilly
LLY
$1.02T
$17.2M 2.13%
222,859
+80,000
+56% +$6.44M
MDT icon
17
Medtronic
MDT
$109B
$16.9M 2.09%
211,283
+47,058
+29% +$3.88M
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$16.7M 2.06%
792,730
-291,851
-27% -$5.69M
BMRN icon
19
BioMarin Pharmaceuticals
BMRN
$11.6B
$16.6M 2.05%
204,849
+65,000
+46% +$5.58M
BDX icon
20
Becton Dickinson
BDX
$45.6B
$16.3M 2%
+76,875
New +$16.8M
IOVA icon
21
Iovance Biotherapeutics
IOVA
$1.82B
$16M 1.97%
944,185
– –
CVS icon
22
CVS Health
CVS
$133B
$15.8M 1.95%
+253,868
New +$18.2M
GKOS icon
23
Glaukos
GKOS
$9.83B
$15.5M 1.91%
503,400
-105,000
-17% -$3.18M
SAGE
24
DELISTED
Sage Therapeutics
SAGE
$15.3M 1.89%
95,000
-9,930
-9% -$1.69M
ESRX
25
DELISTED
Express Scripts Holding Company
ESRX
$14.9M 1.83%
215,000
-6,483
-3% -$495K
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2018 Portfolio in Review

As of Q1 2018, Rhenman & Partners Asset Management held 102 positions worth $811M, up 9.6% from $740M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $48M of net new capital in Q1 2018, opening 7 new positions and adding to 37 existing holdings. Its largest new stake was CVS Health: 253,868 shares worth $15.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Adamas Pharmaceuticals, an estimated $15.2M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2018 buy was CVS Health: 253,868 shares worth $15.8M.
  • Rhenman & Partners Asset Management added most to Bristol-Myers Squibb in Q1 2018, an estimated $14.2M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2018 reduction was Adamas Pharmaceuticals, cutting an estimated $15.2M.
  • Rhenman & Partners Asset Management fully exited Universal Health Services in Q1 2018, selling an estimated $5.94M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $811M portfolio in Q1 2018.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 10 in Q1 2018.
  • Rhenman & Partners Asset Management's portfolio value rose 9.6% quarter-over-quarter to $811M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2018, filed 11 Apr 2018.